The "Anti-Obesity Drugs Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Active Compound Used, Mechanism of Action, Type of Agonist, Action Pathway, Route of Administration, Geographical Regions, Sales Forecast and Key Players" report has been added to ResearchAndMarkets.com's offering.

The global anti-obesity drugs market size is estimated to grow from USD 12.8 billion in the current year to USD 104.9 billion by 2035, at a CAGR of 21.1% during the forecast period, till 2035.

Anti-Obesity Drugs Market: Key Insights

The report delves into the current state of the anti-obesity market and identifies potential growth opportunities within the industry. The key takeaways of the report are:

• Currently, close to 225 drugs are marketed / being developed for the management of obesity; around 50% of these can be administered through oral route
• A sizeable proportion (70%) of big pharma players have entered into various partnerships in order to expand their anti-obesity drug portfolios; majority of these partnerships (~30%) were research and development agreements
• The growing awareness among patients about the health risks, associated with obesity coupled with its increasing prevalence, is driving the anti-obesity market and positioning it for steady growth in the foreseeable future
• The anti-obesity drugs market is anticipated to grow at an annualized rate (CAGR) of 21.1%, till 2035; North America is expected to capture the majority share (~60%) of the market by 2035
• Currently, the centrally acting anti-obesity drugs dominate the market; notably, parenteral route of administration is expected to capture the majority share (~85%) in market by 2035

Anti-Obesity Drugs Market: Key Segments

Small Molecules is the Fastest Growing Segment of the Anti-obesity Drugs Market

• Based on the type of molecule, the global market for anti-obesity is segmented into biologics and small molecules. Currently, the small molecules segment occupies the highest share in the overall market. However, the landscape is likely to evolve as biologics emerge as a promising and more effective alternative that can target the underlying biological pathways associated with obesity.

Semaglutide is Likely to Hold the Largest Share of the Anti-obesity Drugs Market During the Forecast Period

• Based on the active compound used, the global market for anti-obesity is segmented into Tirzepatide, Semaglutide, Retatrutide, Survodutide, Cagrilintide and Semaglutide, Orforglipron, Liraglutide, and other active compounds.Currently, Semaglutide leads the anti-obesity drugs market, and this can be attributed to its strong efficacy in weight management and diabetes control. However, owing to significant research progress, tirzepatide has gained attention for its dual action as both a GLP-1 and GIP receptor agonist, demonstrating superior weight loss results in clinical trials.

Anti-Obesity Drugs Market for GLP-1 agonist is Likely to Grow at a Relatively Faster Pace During the Forecast Period

• Based on the mechanism of action, the global market for anti-obesity is segmented across GLP-1 agonist / GIP agonist, GLP-1 agonist / GCGR agonist, GLP-1 agonist, GLP-1 agonist / amylin analogue, GLP-1 / GCGR / GIP agonist and other mechanisms of action. Presently, the market is dominated by GLP-1 agonists, due to their ability to mimic hormone glucagon-like peptide 1 (GLP-1), thereby promoting significant weight loss.

Anti-Obesity Drugs Market for Single Agonist is Likely to Grow at a Higher CAGR During the Forecast Period

• Based on the type of agonist, the global market for anti-obesity is segmented into single-agonist, dual-agonist and tri-agonist. Currently, single agonist captures the maximum anti-obesity drugs market share owing to its user-friendliness for facilitating patient adherence.

Anti-Obesity Drugs Catering to Centrally Acting Pathways is Likely to Dominate the Anti-Obesity Drugs Market During the Forecast Period

• Based on the action pathway, the global market for anti-obesity is distributed across centrally acting, peripherally acting and, centrally and peripherally acting pathways. Presently, centrally acting segment captures the highest anti-obesity drugs market share and is expected to dominate the market during the forecast period. It is important to note that despite ongoing research into alternative pathways, robust clinical evidence supporting the efficacy of centrally acting agents ensures their continued dominance in the market.

Parenteral Route Hold the Largest Share of the Anti-Obesity Drugs Market

• Based on the routes of administration, the global market for anti-obesity is segmented into oral and parenteral. Currently, the parenteral route captures the majority share of the market, owing to its rapid onset of action and higher bioavailability compared to oral formulations.

North America Accounts for the Largest Share of the Market

• Based on geographical regions, the market is segmented into North America, Europe, Asia-Pacific, and Latin America. In the current scenario, North America is likely to capture the largest market share. This can be attributed to a high prevalence of obesity and related comorbidities, driving the demand for effective treatment options. Additionally, the region benefits from advanced healthcare infrastructure, significant investment in pharmaceutical research, and robust regulatory frameworks that facilitate the development and approval of new therapies.

Key Players in the Anti-Obesity Drugs Market profiled in the report include:

• Eli Lilly
• Pfizer
• Regeneron
• Kallyope
• CinFina Pharma
• Viking Therapeutics
• AstraZeneca
• Novo Nordisk
• Roche
• Adocia
• Boehringer Ingelheim
• Zealand Pharma
• Hanmi Pharm
• Jiangsu Hengrui Pharmaceuticals
• Gmax Biopharma
• PegBio
• QL Biopharm
• Sciwind Biosciences

Anti-Obesity Drugs Market: Research Coverage

The report on anti-obesity drugs market features insights on various sections, including:

• Market Sizing and Opportunity Analysis: An in-depth analysis of current market opportunity and the future growth potential of anti-obesity drugs market, focusing on key market segments, including type of molecule, active compound used, mechanism of action, type of agonist, action pathway, route of administration, and geographical regions.
• Market Impact Analysis: A thorough analysis of various factors, such as drivers, restraints, opportunities, and existing challenges that are likely to impact market growth.
• Market Landscape: A comprehensive evaluation of companies engaged in anti-obesity domain, based on several relevant parameters, such as stage of development, type of molecule, mechanism of action, type of agonist, route of administration, dosage frequency, and type of therapy.
• Anti-obesity Drug Developer Landscape: The report features a list of players engaged in the anti-obesity drug domain, along with analyses based on year of establishment, company size, and location of headquarters, and most active players.
• Company Profiles: In-depth profiles of key industry players in the anti-obesity drug domain, featuring information on company overview, financial information (if available), metaverse in healthcare portfolio, recent developments, and future outlook statements.
• Big Pharma Players: An insightful review of various anti-obesity initiatives undertaken by big pharma players, highlighting trends across various parameters, such as year of initiative, type of initiative, number of partnerships, type of partnership, and type of expansion.

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Key Topics Covered:

1. BACKGROUND

2. RESEARCH METHODOLOGY

3. MARKET DYNAMICS

4. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Overview of Anti-Obesity Drugs

6.2. Health Risks Linked with Long-term Obesity

6.3. Currently Approved Anti-Obesity Drug Classes

6.4. Challenges Associated with Anti-Obesity Drugs

6.5. Future Perspectives

7. MARKET LANDSCAPE: ANTI-OBESITY DRUGS

7.1. Market Landscape: Anti-Obesity Drugs

7.2. Developer Landscape: Anti-Obesity Drugs

8. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN NORTH AMERICA

Detailed Company Profiles

• Eli Lilly
• Pfizer
• Regeneron

Brief Company Profiles

• CinFina Pharma
• Kallyope
• Viking Therapeutics

9. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN EUROPE

Detailed Company Profiles

• AstraZeneca
• Novo Nordisk
• Roche

Brief Company Profiles

• Adocia
• Boehringer Ingelheim
• Zealand Pharma

10. COMPANY PROFILES: ANTI-OBESITY DRUG DEVELOPERS BASED IN ASIA-PACIFIC AND REST OF THE WORLD

Detailed Company Profiles

• Hanmi Pharmaceuticals
• Jiangsu Hengrui Pharmaceuticals

Brief Company Profiles

• GMAX Biopharma
• PegBio
• QL Biopharm
• Sciwind Biosciences

11. BIG PHARMA INITIATIVES

Big Pharma Players: Anti-obesity focused Initiatives

• Analysis of Big Pharma Players by Number of Initiatives
• Analysis by Year of Initiative
• Analysis by Big Pharma Player by Year of Initiative and Number of Initiatives
• Analysis by Type of Initiative
• Analysis by Year and Type of Initiative
• Analysis by Big Pharma Player and Type of Initiative
• Analysis by Big Pharma Player and Number of Partnerships
• Analysis by Type of Partnership
• Analysis by Type of Expansion
• Analysis by Big Pharma Player by Region and Number of Initiatives
• Benchmarking of Big Pharma Players

12. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

13. GLOBAL ANTI-OBESITY DRUGS MARKET

14. ANTI-OBESITY DRUGS MARKET, BY TYPE OF MOLECULE

15. ANTI-OBESITY DRUGS MARKET, BY ACTIVE COMPOUND USED

• Anti-Obesity Drugs Market for Tirzepatide
• Anti-Obesity Drugs Market for Semaglutide
• Anti-Obesity Drugs Market for Retatrutide
• Anti-Obesity Drugs Market for Survodutide
• Anti-Obesity Drugs Market for Cagrilintide and Semglutide
• Anti-Obesity Drugs Market for Orforglipron
• Anti-Obesity Drugs Market for Liraglutide
• Anti-Obesity Drugs Market for other active compounds used, Historical Trends (since 2019) and Forecasted Estimates (till 2035)

16. ANTI-OBESITY DRUGS MARKET, BY MECHANISM OF ACTION

17. ANTI-OBESITY DRUGS MARKET, BY TYPE OF AGONIST

• Anti-Obesity Drugs Market for Single-Agonist
• Anti-Obesity Drugs Market for Dual-Agonist
• Anti-Obesity Drugs Market for Tri-Agonist

18. ANTI-OBESITY DRUGS MARKET, BY ACTION PATHWAY

• Anti-Obesity Drugs Market for Centrally Acting Drugs
• Anti-Obesity Drugs Market for Peripherally Acting Drugs
• Anti-Obesity Drugs Market for Centrally Acting and Peripherally Acting Drugs

19. ANTI-OBESITY DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• Anti-Obesity Drugs Market for Oral Administration
• Anti-Obesity Drugs Market for Parenteral Administration

20. ANTI-OBESITY DRUGS MARKET, BY GEOGRAPHICAL REGIONS

21. ANTI-OBESITY DRUGS MARKET, SALES FORECAST OF MARKETED AND PHASE III DRUGS

Marketed Drugs: Sales Forecast

• Contrave / Mysimba (Naltrexone, Bupropion)
• Feisumei (Beinaglutide)
• Imcivree (Setmelanotide)
• LOMAIRA (Phentermine Hydrochloride)
• QSYMIA (Phentermine and Topiramate)
• Saxenda (Liraglutide)
• Wegovy / Ozempic (Semaglutide)
• Zepbound / Mounjaro (Tirzepatide)

Phase III Drugs: Sales Forecast

• BI 456906 (Survodutide)
• CagriSema (Cagrilintide and Semaglutide)
• HM11260C (Efpeglenatide)
• HRS-9531
• IBI362 (Mazdutide)
• LM-008
• LY3437943 (Retatrutide)
• LY3502970 (Orforglipron)
• TG103
• Semaglutide 7.2 mg (Subcutaneous)
• Semaglutide (Oral)
• XW003

22. ANTI-OBESITY DRUGS MARKET, BY KEY PLAYERS

For more information about this report visit https://www.researchandmarkets.com/r/873t71

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250331342314/en/